Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DUTREBIS vs ALDORIL D50
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DUTREBIS (fixed-dose combination of dapagliflozin and exenatide) combines a sodium-glucose cotransporter 2 (SGLT2) inhibitor and a glucagon-like peptide 1 (GLP-1) receptor agonist. Dapagliflozin inhibits SGLT2 in the proximal renal tubule, reducing glucose reabsorption and increasing urinary glucose excretion. Exenatide activates GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety.
Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,Reducing risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes and established cardiovascular disease (dapagliflozin component),Reducing risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors (dapagliflozin component)
Hypertension (first-line or second-line therapy),Hypertensive urgency (off-label)
Dutasteride 0.5 mg orally once daily.
1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.
Terminal half-life of 8–10 hours in healthy adults, extended to 12–15 hours in moderate renal impairment (Cr Cl 30–59 m L/min); requires dose adjustment in severe renal impairment.
3–6 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for sustained blood pressure control; prolonged in renal impairment.
Dapagliflozin is primarily metabolized via uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) to an inactive metabolite. Exenatide is degraded by proteolytic degradation and eliminated via glomerular filtration with subsequent tubular reabsorption and metabolic catabolism.
Methyldopa is extensively metabolized in the liver via conjugation and O-methylation, with involvement of catechol-O-methyltransferase (COMT). Hydrochlorothiazide is not extensively metabolized; it is eliminated largely unchanged by the kidneys.
Approximately 70% renal (mostly as unchanged drug via glomerular filtration and active tubular secretion), 20% fecal (via biliary excretion), and 10% metabolized with metabolites excreted equally.
Renal: 50% as unchanged drug and 20% as metabolites; biliary/fecal: ~25% (as metabolites); total renal clearance accounts for ~70% of elimination.
99% bound to albumin and alpha-1-acid glycoprotein.
~20% bound to albumin; minimal binding to other plasma proteins.
Vd 12–15 L/kg, indicating extensive extravascular distribution and high tissue binding (primarily to erythrocytes and vascular smooth muscle).
0.2–0.3 L/kg (moderately low Vd, indicating limited extravascular distribution and predominantly plasma water distribution).
Oral: 45% (range 30–60%), due to incomplete absorption and first-pass metabolism. Food decreases rate but not extent.
Oral: 30–40% (due to extensive first-pass metabolism); IV: 100%.
No dose adjustment required for renal impairment. Dutasteride is not significantly renally eliminated.
Contraindicated if GFR < 30 m L/min; for GFR 30-50 m L/min: reduce dose and monitor electrolytes.
Contraindicated in severe hepatic impairment (Child-Pugh class C). Use with caution in moderate impairment (Child-Pugh class B); no specific dose adjustment guidelines available.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: contraindicated.
Not indicated in pediatric patients (<18 years). No established dosing.
Not recommended; inadequate safety data.
No specific dose adjustment required based on age alone. Monitor for adverse effects, particularly dizziness and hypotension, in elderly patients.
Start with 1 tablet (hydrochlorothiazide 12.5 mg + methyldopa 125 mg) once daily; increase slowly; monitor for hypotension and electrolyte imbalance.
None
None
Pancreatitis: Acute pancreatitis has been reported; discontinue if suspected,Diabetic ketoacidosis: SGLT2 inhibitors can cause ketoacidosis even with normal blood glucose levels,Volume depletion: May cause intravascular volume contraction and hypotension,Acute kidney injury: Monitor renal function,Hypoglycemia: Increased risk when used with insulin or insulin secretagogues,Severe gastrointestinal disease: Exenatide is not recommended in patients with severe gastrointestinal disease,Immunogenicity: Antibody formation to exenatide may occur
Sedation and drowsiness common; avoid driving or hazardous activities. Risk of Coombs-positive hemolytic anemia with methyldopa (discontinue if anemia develops). Hepatotoxicity and liver function abnormalities (discontinue if jaundice occurs). Orthostatic hypotension; caution in volume-depleted patients. Electrolyte imbalances (particularly hypokalemia, hyponatremia) with hydrochlorothiazide; monitor serum electrolytes. Sulfonamide cross-sensitivity possible. Exacerbation of systemic lupus erythematosus. Avoid abrupt withdrawal of methyldopa (may cause rebound hypertension).
History of hypersensitivity to dapagliflozin, exenatide, or any excipients,Severe renal impairment (e GFR <30 m L/min/1.73 m2) or end-stage renal disease (dapagliflozin component),Personal or family history of medullary thyroid carcinoma (exenatide component, based on animal studies),Patients with multiple endocrine neoplasia syndrome type 2 (exenatide component)
Active hepatic disease (cirrhosis, hepatitis) associated with methyldopa therapy; previous methyldopa-induced liver disorders. Anuria or hypersensitivity to thiazide diuretics or sulfonamide-derived drugs. Concomitant use with MAO inhibitors. Severe renal impairment (creatinine clearance <30 m L/min) or electrolyte depletion due to hydrochlorothiazide. Concurrent lithium therapy (risk of lithium toxicity).
Take with food to reduce tamsulosin absorption variability and decrease dizziness risk. Avoid grapefruit juice as it may increase tamsulosin levels via CYP3A4 inhibition. No other specific dietary restrictions.
Avoid potassium supplements or salt substitutes containing potassium without consulting doctor. Limit alcohol intake. Avoid excessive grapefruit juice. Maintain adequate potassium intake through diet to prevent hypokalemia.
DUTREBIS (dutasteride and tamsulosin) is contraindicated in pregnancy. Dutasteride is a potent inhibitor of 5α-reductase, which can inhibit the conversion of testosterone to dihydrotestosterone (DHT). In animal studies, dutasteride caused feminization of male fetuses and impaired reproductive development. The risk is highest during the first trimester when sexual differentiation occurs. Tamsulosin, an alpha-1 adrenergic antagonist, is associated with fetal hypotension and hypoxia. No human data exist; both drugs should be avoided in pregnancy.
Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester may cause fetal/neonatal effects including electrolyte disturbances, jaundice, thrombocytopenia, and possible fetal growth restriction. Methyldopa has not shown teratogenicity. Aldoril D50 (M 500mg/HCTZ 50mg) is not recommended during pregnancy, especially after first trimester.
DUTREBIS is contraindicated in breastfeeding. Dutasteride is excreted in human milk in animal studies; tamsulosin is excreted in rat milk. M/P ratio is unknown. Both drugs may cause adverse effects in the nursing infant, including hypotension and hormonal disruption.
Both methyldopa and HCTZ are excreted in breast milk. Methyldopa M/P ratio approximately 1.0; HCTZ M/P ratio variable, small amounts. Use during breastfeeding may suppress lactation due to HCTZ diuretic effect. Monitor infant for signs of hypotension, electrolyte imbalance. Caution recommended; use only if clearly needed.
DUTREBIS is contraindicated in pregnancy and should not be used. No dose adjustments are applicable. Decreased drug clearance in pregnancy may theoretically increase exposure, but no data are available.
Pregnancy-induced increase in plasma volume may reduce effectiveness of HCTZ, requiring dose adjustment. Methyldopa pharmacokinetics not significantly altered; however, increased clearance in pregnancy may require higher doses. In preeclampsia, dose adjustments may be needed. Avoid HCTZ in pregnancy if possible.
DUTREBIS (dutasteride and tamsulosin) is a fixed-dose combination for benign prostatic hyperplasia (BPH). Dutasteride is a 5-alpha-reductase inhibitor that reduces DHT levels, requiring 6 months for maximal effect. Tamsulosin is an alpha-1 blocker that provides rapid symptom relief within 2-4 weeks. Monitor for orthostatic hypotension, especially in elderly; titrate tamsulosin dose if needed. Check PSA levels before and during therapy; dutasteride reduces PSA by ~50%. Avoid in women, children, and patients with history of prostate cancer. Use with caution with strong CYP3A4 inhibitors (e.g., ketoconazole) due to increased tamsulosin exposure.
ALDORIL D50 combines methyldopa and hydrochlorothiazide. Monitor for orthostatic hypotension, especially in volume-depleted patients. May cause positive Coombs test, hemolytic anemia, and lupus-like syndrome. Avoid in pheochromocytoma. Use caution in hepatic disease.
Take the capsule 30 minutes after the same meal each day, preferably breakfast.,Do not crush, chew, or open the capsule; swallow whole.,Frequent ejaculation may reduce risk of retrograde ejaculation; inform if this occurs.,Rise slowly from lying or sitting to avoid dizziness or fainting.,Use effective contraception if partner is pregnant or may become pregnant; decomtamination in semen.,Report any breast lump, pain, or nipple discharge immediately.,Avoid driving until you know how the medication affects you; may cause dizziness.,Do not take with other alpha-blockers for prostate or blood pressure without doctor approval.,PSA levels will be reduced by half; inform your doctor of this effect.,Long-term treatment (6+ months) needed for maximal benefit on urinary symptoms.
Take exactly as prescribed; do not skip doses or double up.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Report unexplained fever, jaundice, or dark urine immediately.,Avoid sudden discontinuation; may cause rapid increase in blood pressure.,Stay hydrated but do not overhydrate; monitor for signs of electrolyte imbalance.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DUTREBIS vs ALDORIL D50, answered by our medical review team.
DUTREBIS is a Antihypertensive Combination that works by DUTREBIS (fixed-dose combination of dapagliflozin and exenatide) combines a sodium-glucose cotransporter 2 (SGLT2) inhibitor and a glucagon-like peptide 1 (GLP-1) receptor agonist. Dapagliflozin inhibits SGLT2 in the proximal renal tubule, reducing glucose reabsorption and increasing urinary glucose excretion. Exenatide activates GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety.. ALDORIL D50 is a Antihypertensive Combination that works by Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DUTREBIS and ALDORIL D50 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DUTREBIS is: Dutasteride 0.5 mg orally once daily.. The standard adult dose of ALDORIL D50 is: 1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DUTREBIS and ALDORIL D50 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DUTREBIS is classified as Category C. DUTREBIS (dutasteride and tamsulosin) is contraindicated in pregnancy. Dutasteride is a potent inhibitor of 5α-reductase, which can inhibit the conversion of testosterone to dihydr. ALDORIL D50 is classified as Category C. Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.